SML0309
Sodium phenylbutyrate
≥98% (HPLC), histone deacetylase inhibitor, powder
Synonym(s):
4-PBA, 4-Phenylbutyric acid, 4-phenylbutyrate, Buphenyl, Sodium 4-phenylbutyrate, TriButyrate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C10H11NaO2
CAS Number:
Molecular Weight:
186.18
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Sodium phenylbutyrate, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: ≥5 mg/mL
storage temp.
room temp
SMILES string
[Na+].[O-]C(=O)CCCc1ccccc1
InChI
1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
InChI key
VPZRWNZGLKXFOE-UHFFFAOYSA-M
General description
Sodium phenylbutyrate stimulates urinary nitrogen excretion. It is a prodrug, which undergoes β-oxidation to phenylacetate. Sodium phenylbutyrate is used to treat urea cycle disorder. It might be associated with menstrual dysfunction, amenorrhea and painful mucositis of the esophagus and stomach.
Application
Sodium phenylbutyrate has been used as an endoplasmic reticulum (ER) stress inhibitor to study the role of ER stress in the expression of betatrophin.
Biochem/physiol Actions
Sodium phenylbutyrate is a histone deacetylase inhibitor.
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Still not finding the right product?
Explore all of our products under Sodium phenylbutyrate
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control
Lee B, et al.
Molecular Genetics and Metabolism, 100(3), 221-228 (2010)
Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies
Lee YH, et al.
Scientific Reports, 6(3), 24013-24013 (2016)
Advances in Clinical Chemistry, Volume 17 (2014)